14 September 2023
14 September 2023
ICON will conduct Phase IIb clinical trials for the US BARDA-selected Covid-19 vaccine candidates as part of Project NextGen.
After accusing its former partner, Nektar bounces back with new planned trials in AD and alopecia areata.
The pathological complete response rate is the primary efficacy endpoint of the study.
The key goal of the study is to determine whether epetraborole plus an OBR is superior to placebo plus OBR.
The company is investigating an artificial urinary sphincter that automatically controls urethral pressure depending on patient activity.
Roche planned to launch the new formulation this year, but it will be pushed back after tweaks requested by FDA.
Patients will receive 2mg/kg of RGLS8429 or placebo every other week for three months.
The company plans to initiate a Phase II expansion arm of the study to evaluate immune responses and disease marker activity.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.
Give your business an edge with our leading industry insights.
